Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

Anders H. Andersen; Charles D. Smith; John T. Slevin; Richard J. Kryscio; Catherine A. Martin; Frederick A. Schmitt; Lee X. Blonder

doi:10.1155/2015/513452

Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

Anders H. Andersen, Charles D. Smith, John T. Slevin, Richard J. Kryscio, Catherine A. Martin, Frederick A. Schmitt, Lee X. Blonder

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

Original language	English
Article number	513452
Journal	Parkinson's Disease
Volume	2015
DOIs	https://doi.org/10.1155/2015/513452
State	Published - 2015

Bibliographical note

Publisher Copyright:
© 2015 Anders H. Andersen et al.

Funding

This work was supported by the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke Grant R01MH78228 (Lee X. Blonder) and by the Department of Veterans Affairs (John T. Slevin).

Funders	Funder number
National Institute of Mental Health
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council	R01MH78228
Institute of Neurological Disorders and Stroke National Advisory Neurological Disorders and Stroke Council
U.S. Department of Veterans Affairs

ASJC Scopus subject areas

Neuroscience (miscellaneous)
Clinical Neurology
Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2015/513452

Cite this

@article{9dea169fd823435cb52e348beacd0089,

title = "Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression",

abstract = "Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.",

author = "Andersen, {Anders H.} and Smith, {Charles D.} and Slevin, {John T.} and Kryscio, {Richard J.} and Martin, {Catherine A.} and Schmitt, {Frederick A.} and Blonder, {Lee X.}",

note = "Publisher Copyright: {\textcopyright} 2015 Anders H. Andersen et al.",

year = "2015",

doi = "10.1155/2015/513452",

language = "English",

volume = "2015",

}

TY - JOUR

T1 - Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

AU - Andersen, Anders H.

AU - Smith, Charles D.

AU - Slevin, John T.

AU - Kryscio, Richard J.

AU - Martin, Catherine A.

AU - Schmitt, Frederick A.

AU - Blonder, Lee X.

PY - 2015

Y1 - 2015

N2 - Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

AB - Parkinson's disease (PD) is associated with emotional abnormalities. Dopaminergic medications ameliorate Parkinsonian motor symptoms, but less is known regarding the impact of dopaminergic agents on affective processing, particularly in depressed PD (dPD) patients. The aim of this study was to examine the effects of dopaminergic pharmacotherapy on brain activation to emotional stimuli in depressed versus nondepressed Parkinson disease (ndPD) patients. Participants included 18 ndPD patients (11 men, 7 women) and 10 dPD patients (7 men, 3 women). Patients viewed photographs of emotional faces during functional MRI. Scans were performed while the patient was taking anti-Parkinson medication and the day after medication had been temporarily discontinued. Results indicate that dopaminergic medications have opposite effects in the prefrontal cortex depending upon depression status. DPD patients show greater deactivation in the ventromedial prefrontal cortex (VMPFC) on dopaminergic medications than off, while ndPD patients show greater deactivation in this region off drugs. The VMPFC is in the default-mode network (DMN). DMN activity is negatively correlated with activity in brain systems used for external visual attention. Thus dopaminergic medications may promote increased attention to external visual stimuli among dPD patients but impede normal suppression of DMN activity during external stimulation among ndPD patients.

UR - http://www.scopus.com/inward/record.url?scp=84953791052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953791052&partnerID=8YFLogxK

U2 - 10.1155/2015/513452

DO - 10.1155/2015/513452

M3 - Article

AN - SCOPUS:84953791052

SN - 2090-8083

VL - 2015

JO - Parkinson's Disease

JF - Parkinson's Disease

M1 - 513452

ER -

Dopaminergic Modulation of Medial Prefrontal Cortex Deactivation in Parkinson Depression

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this